|
US7935812B2
(en)
|
2002-02-20 |
2011-05-03 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
|
CA2491164C
(en)
|
2002-06-28 |
2012-05-08 |
Cory Giesbrecht |
Method and apparatus for producing liposomes
|
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
KR101168440B1
(ko)
|
2003-07-16 |
2012-07-27 |
프로티바 바이오쎄라퓨틱스, 인코포레이티드 |
지질 캡슐화된 간섭 rna
|
|
ES2423060T3
(es)
|
2004-03-12 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Agentes iRNA que tienen como diana al VEGF
|
|
US7303881B2
(en)
*
|
2004-04-30 |
2007-12-04 |
Pds Biotechnology Corporation |
Antigen delivery compositions and methods of use
|
|
ATE537263T1
(de)
|
2004-06-07 |
2011-12-15 |
Protiva Biotherapeutics Inc |
Kationische lipide und verwendungsverfahren
|
|
WO2005121348A1
(en)
|
2004-06-07 |
2005-12-22 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
|
US7807815B2
(en)
|
2004-07-02 |
2010-10-05 |
Protiva Biotherapeutics, Inc. |
Compositions comprising immunostimulatory siRNA molecules and DLinDMA or DLenDMA
|
|
US20060134189A1
(en)
*
|
2004-11-17 |
2006-06-22 |
Protiva Biotherapeutics, Inc |
siRNA silencing of apolipoprotein B
|
|
WO2006074546A1
(en)
*
|
2005-01-13 |
2006-07-20 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
|
US7404969B2
(en)
|
2005-02-14 |
2008-07-29 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
|
EP1922300A2
(de)
|
2005-02-14 |
2008-05-21 |
Sirna Therapeutics Inc. |
Kationische lipide und diese enthaltende formulierte molekulare zusammensetzungen
|
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
|
GB2430881B
(en)
*
|
2005-10-06 |
2010-10-13 |
Ntnu Technology Transfer As |
Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
|
|
WO2007048046A2
(en)
|
2005-10-20 |
2007-04-26 |
Protiva Biotherapeutics, Inc. |
Sirna silencing of filovirus gene expression
|
|
AU2006308765B2
(en)
|
2005-11-02 |
2013-09-05 |
Arbutus Biopharma Corporation |
Modified siRNA molecules and uses thereof
|
|
EP2835429B1
(de)
|
2006-05-11 |
2017-12-13 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und Verfahren zur Hemmung der PCSK9-Genexpression
|
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
CA2656228C
(en)
*
|
2006-06-30 |
2016-02-09 |
Hokkaido System Science Co., Ltd. |
Composition for nucleic-acid transfection
|
|
CA2661292A1
(en)
*
|
2006-08-24 |
2008-02-28 |
British Columbia Cancer Agency Branch |
Compositions and methods for treating myelosuppression
|
|
ES2611924T3
(es)
|
2006-10-03 |
2017-05-11 |
Arbutus Biopharma Corporation |
Formulaciones que contienen lípidos
|
|
EP2123259A1
(de)
*
|
2007-01-16 |
2009-11-25 |
Hokkaido University |
Liposom-zubereitung für die iontophorese mit einem darin eingekapselten antioxidans-bestandteil
|
|
US9273300B2
(en)
*
|
2007-02-07 |
2016-03-01 |
Strike Bio, Inc |
Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy
|
|
US8877206B2
(en)
|
2007-03-22 |
2014-11-04 |
Pds Biotechnology Corporation |
Stimulation of an immune response by cationic lipids
|
|
GB0707096D0
(en)
*
|
2007-04-12 |
2007-05-23 |
Ntnu Technology Transfer As |
Method
|
|
JP2010187707A
(ja)
*
|
2007-06-12 |
2010-09-02 |
Hokkaido Univ |
インスリンを封入したイオントフォレーシス用リポソーム製剤
|
|
WO2009021325A1
(en)
|
2007-08-10 |
2009-02-19 |
British Columbia Cancer Agency Branch |
Microrna compositions and methods for the treatment of myelogenous leukemia
|
|
KR100807060B1
(ko)
*
|
2007-08-28 |
2008-02-25 |
고려대학교 산학협력단 |
신규한 양이온성 지질, 그의 제조 방법 및 그를 포함하는전달체
|
|
CA2710713C
(en)
|
2007-12-27 |
2017-09-19 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering rna
|
|
JP5749494B2
(ja)
*
|
2008-01-02 |
2015-07-15 |
テクミラ ファーマシューティカルズ コーポレイション |
核酸の送達のための改善された組成物および方法
|
|
EP2245039A4
(de)
*
|
2008-01-31 |
2012-06-06 |
Alnylam Pharmaceuticals Inc |
Optimierte verfahren zur ausgabe von dsrna zum abzielen auf das gen pcsk9
|
|
EP2265276A2
(de)
*
|
2008-03-05 |
2010-12-29 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur unterdrückung der expression von eg5 und vegf-genen
|
|
CN102119217B
(zh)
*
|
2008-04-15 |
2015-06-03 |
普洛体维生物治疗公司 |
用于核酸递送的新型制剂
|
|
JP2011516094A
(ja)
|
2008-04-15 |
2011-05-26 |
プロチバ バイオセラピューティクス インコーポレイティッド |
干渉rnaを用いたcsn5遺伝子発現のサイレンシング方法
|
|
WO2009129387A2
(en)
*
|
2008-04-16 |
2009-10-22 |
Abbott Laboratories |
Cationic lipids and uses thereof
|
|
EP2276495B1
(de)
|
2008-04-17 |
2018-11-21 |
PDS Biotechnology Corporation |
Stimulierung einer immunantwort durch enantiomere von kationischen lipiden
|
|
JP5299424B2
(ja)
|
2008-06-19 |
2013-09-25 |
日本新薬株式会社 |
薬物担体
|
|
EP2326331A4
(de)
*
|
2008-08-18 |
2013-05-15 |
Merck Sharp & Dohme |
Neue lipidnanopartikel und neue komponenten zur freisetzung von nukleinsäuren
|
|
US8546554B2
(en)
|
2008-09-25 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
|
|
CA2740000C
(en)
*
|
2008-10-09 |
2017-12-12 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
MX344354B
(es)
|
2008-10-20 |
2016-12-14 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion de transtiretina.
|
|
EP2350670B1
(de)
|
2008-10-30 |
2018-06-06 |
Peixuan Guo |
In eine membran integrierter protein-konnektor-biosensor für virale dna-verpackungsmotoren zur dna-sequenzierung und für andere verwendungen
|
|
SG10201901089TA
(en)
|
2008-11-10 |
2019-03-28 |
Arbutus Biopharma Corp |
Novel lipids and compositions for the delivery of therapeutics
|
|
US8957199B2
(en)
|
2008-11-26 |
2015-02-17 |
Chugai Seiyaku Kabushiki Kaisha |
Oligoribonucleotide or peptide nucleic acid capable of inhibiting activity of hepatitis C virus
|
|
JP5600299B2
(ja)
*
|
2008-11-26 |
2014-10-01 |
中外製薬株式会社 |
ベシクル製剤
|
|
EP2373382B1
(de)
|
2008-12-10 |
2017-02-15 |
Alnylam Pharmaceuticals, Inc. |
Auf gnaq zielende dsrna-zusammensetzungen und verfahren zur unterdrückung der expression
|
|
EP2406376A1
(de)
*
|
2009-03-12 |
2012-01-18 |
Alnylam Pharmaceuticals, Inc. |
Lipidformulierte zusammensetzungen und verfahren zur hemmung der expression von eg5- und vegf-genen
|
|
GB0904941D0
(en)
*
|
2009-03-23 |
2009-05-06 |
Ntnu Technology Transfer As |
Composition
|
|
GB0904942D0
(en)
|
2009-03-23 |
2009-05-06 |
Ntnu Technology Transfer As |
Composition
|
|
JP5889783B2
(ja)
*
|
2009-05-05 |
2016-03-22 |
テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation |
免疫細胞へオリゴヌクレオチドを送達する方法
|
|
AU2010249881B2
(en)
|
2009-05-16 |
2015-01-22 |
Agave Pharma, Incorporated |
Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules
|
|
SMT202100696T1
(it)
*
|
2009-06-10 |
2022-01-10 |
Arbutus Biopharma Corp |
Formulazione lipidica migliorata
|
|
EA201270019A1
(ru)
|
2009-06-15 |
2012-06-29 |
Элнилэм Фармасьютикалз, Инк. |
Двуцепочечная рнк, включенная в липидный состав и мишенью которой является ген pcsk9
|
|
WO2010147992A1
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Methods for increasing efficacy of lipid formulated sirna
|
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
|
WO2011000108A1
(en)
*
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein b
|
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
|
US9029338B2
(en)
|
2009-08-14 |
2015-05-12 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
|
WO2011022460A1
(en)
|
2009-08-20 |
2011-02-24 |
Merck Sharp & Dohme Corp. |
Novel cationic lipids with various head groups for oligonucleotide delivery
|
|
WO2011038031A1
(en)
|
2009-09-22 |
2011-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dual targeting sirna agents
|
|
EP2480668A2
(de)
|
2009-09-23 |
2012-08-01 |
Protiva Biotherapeutics Inc. |
Zusammensetzungen und verfahren zur ausschaltung von in krebs exprimierten genen
|
|
EP3252068B1
(de)
|
2009-10-12 |
2025-07-02 |
Larry J. Smith |
Verfahren und zusammensetzungen zur modulation der genexpression unter verwendung in-vivo- oder in-vitro-verabreichten arzneistoffen auf oligonukleotidbasis
|
|
WO2011056682A1
(en)
|
2009-10-27 |
2011-05-12 |
The University Of British Columbia |
Reverse head group lipids, lipid particle compositions comprising reverse headgroup lipids, and methods for the delivery of nucleic acids
|
|
EP2496238A4
(de)
|
2009-11-03 |
2013-10-02 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der transthyretinexpression
|
|
CN107028886A
(zh)
|
2009-11-04 |
2017-08-11 |
不列颠哥伦比亚大学 |
含有核酸的脂质粒子及相关的方法
|
|
EP3403647A1
(de)
*
|
2009-12-01 |
2018-11-21 |
Translate Bio, Inc. |
Ausgabe von mrna zur vermehrung von proteinen und enzymen bei humangenetischen erkrankungen
|
|
EP2525781A1
(de)
|
2010-01-22 |
2012-11-28 |
Schering Corporation |
Neue kationische lipide zur abgabe von oligonukleotiden
|
|
WO2011109294A1
(en)
*
|
2010-03-01 |
2011-09-09 |
Dicerna Pharmaceuticals, Inc. |
Lipid delivery formulations
|
|
JP2013528665A
(ja)
|
2010-03-26 |
2013-07-11 |
メルサナ セラピューティックス, インコーポレイテッド |
ポリヌクレオチドの送達のための修飾ポリマー、その製造方法、およびその使用方法
|
|
EP2558074B1
(de)
|
2010-04-08 |
2018-06-06 |
The Trustees of Princeton University |
Herstellung von lipidnanopartikeln
|
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
|
JP2013527856A
(ja)
|
2010-05-12 |
2013-07-04 |
プロチバ バイオセラピューティクス インコーポレイティッド |
陽イオン性脂質およびその使用方法
|
|
US8802863B2
(en)
|
2010-05-24 |
2014-08-12 |
Sirna Therapeutics, Inc. |
Amino alcohol cationic lipids for oligonucleotide delivery
|
|
DK2575767T3
(en)
*
|
2010-06-04 |
2017-03-13 |
Sirna Therapeutics Inc |
HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES
|
|
US20130164380A1
(en)
|
2010-06-17 |
2013-06-27 |
Actogenix Nv |
Compositions and methods for treating inflammatory conditions
|
|
WO2012000104A1
(en)
|
2010-06-30 |
2012-01-05 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
DK3243526T3
(da)
|
2010-07-06 |
2020-02-17 |
Glaxosmithkline Biologicals Sa |
Levering af rna til at udløse flere immunsignalveje
|
|
CA2804492A1
(en)
|
2010-07-06 |
2012-01-12 |
Novartis Ag |
Immunisation of large mammals with low doses of rna
|
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
|
JP2013537518A
(ja)
*
|
2010-07-06 |
2013-10-03 |
ノバルティス アーゲー |
RNA送達に有利なpKa値を有する脂質を含むリポソーム
|
|
EP4180057A1
(de)
|
2010-07-06 |
2023-05-17 |
GlaxoSmithKline Biologicals S.A. |
Virionabgabepartikel für selbstreplizierende rna-moleküle
|
|
US20130323269A1
(en)
*
|
2010-07-30 |
2013-12-05 |
Muthiah Manoharan |
Methods and compositions for delivery of active agents
|
|
WO2012017208A1
(en)
|
2010-08-04 |
2012-02-09 |
Cizzle Biotechnology Limited |
Methods and compounds for the diagnosis and treatment of
|
|
EP3578205A1
(de)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
|
|
US20130189351A1
(en)
*
|
2010-08-31 |
2013-07-25 |
Novartis Ag |
Lipids suitable for liposomal delivery of protein coding rna
|
|
EP2611927B1
(de)
|
2010-08-31 |
2018-08-01 |
Sirna Therapeutics, Inc. |
Neue einzelne chemische einheiten sowie verfahren zur abgabe von oligonukleotiden
|
|
FI4066857T3
(fi)
|
2010-08-31 |
2023-03-20 |
Glaxosmithkline Biologicals Sa |
Pegyloituja liposomeja immunogeeniä koodaavan rna:n kuljettamiseksi
|
|
FI4043040T3
(fi)
*
|
2010-08-31 |
2023-04-04 |
Glaxosmithkline Biologicals Sa |
Pieniä liposomeja immunogeeniä koodaavan rna:n toimittamiseksi
|
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
|
MX384381B
(es)
|
2010-09-20 |
2025-03-14 |
Merck Sharp & Dohme |
Lípidos catiónicos novedosos de bajo peso molecular para la entrega de oligonucleótidos.
|
|
US9029604B2
(en)
|
2010-09-30 |
2015-05-12 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
EP4108671B1
(de)
|
2010-10-01 |
2024-11-20 |
ModernaTX, Inc. |
Modifizierte nukleoside, nukleotide und nukleinsäuren und ihre verwendungen
|
|
RU2597974C2
(ru)
|
2010-10-11 |
2016-09-20 |
Новартис Аг |
Платформы доставки антигенов
|
|
CA2813024A1
(en)
|
2010-10-21 |
2012-04-26 |
Merck Sharp & Dohme Corp. |
Novel low molecular weight cationic lipids for oligonucleotide delivery
|
|
DK2632472T3
(en)
*
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
|
EP2635265B1
(de)
|
2010-11-05 |
2018-04-04 |
Sirna Therapeutics, Inc. |
Neuartige zyklische amine von geringem molekulargewicht mit kationischen lipiden zur oligonukleotidabgabe
|
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
|
WO2012108397A1
(ja)
*
|
2011-02-08 |
2012-08-16 |
第一三共株式会社 |
新規脂質
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
US8747891B2
(en)
|
2011-05-10 |
2014-06-10 |
The Penn State Research Foundation |
Ceramide anionic liposome compositions
|
|
PT2717893T
(pt)
|
2011-06-08 |
2019-08-20 |
Translate Bio Inc |
Composições de nanopartículas lipídicas e métodos para transferência de arnm
|
|
EP4074693A1
(de)
|
2011-06-08 |
2022-10-19 |
Translate Bio, Inc. |
Spaltbare lipide
|
|
WO2013006838A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
|
EP4115875A1
(de)
*
|
2011-07-06 |
2023-01-11 |
GlaxoSmithKline Biologicals S.A. |
Liposomen mit nützlichem n:p-verhältnis zur freisetzung von rna-molekülen
|
|
EP2750707B1
(de)
*
|
2011-08-31 |
2018-10-24 |
GlaxoSmithKline Biologicals SA |
Pegylierte liposome zur freisetzung von immunogen-codierender rna
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
PL3682905T3
(pl)
|
2011-10-03 |
2022-04-04 |
Modernatx, Inc. |
Modyfikowane nukleozydy, nukleotydy i kwasy nukleinowe oraz ich zastosowania
|
|
EP3170899B1
(de)
|
2011-10-11 |
2020-06-24 |
The Brigham and Women's Hospital, Inc. |
Mikro-rna mir-155 in neurodegenerativen erkrankungen
|
|
US20140328759A1
(en)
|
2011-10-25 |
2014-11-06 |
The University Of British Columbia |
Limit size lipid nanoparticles and related methods
|
|
IL284530B
(en)
|
2011-11-18 |
2022-07-01 |
Alnylam Pharmaceuticals Inc |
rnai factors, preparations and methods of using them for the treatment of transthyretin-related diseases
|
|
WO2013086373A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
CA2856742A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
EP2792367A4
(de)
*
|
2011-12-12 |
2015-09-30 |
Kyowa Hakko Kirin Co Ltd |
Lipid-nanopartikel für ein arzneimittelverabreichungssystem mit kationischen lipiden
|
|
KR20140111272A
(ko)
*
|
2011-12-12 |
2014-09-18 |
교와 핫꼬 기린 가부시키가이샤 |
양이온성 지질의 조합을 함유하는 지질 나노 입자
|
|
PL2791160T3
(pl)
|
2011-12-16 |
2022-06-20 |
Modernatx, Inc. |
Kompozycje zmodyfikowanego mrna
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
CN110003030A
(zh)
|
2012-02-24 |
2019-07-12 |
野草莓树生物制药公司 |
三烷基阳离子脂质及其使用方法
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
JP6232416B2
(ja)
|
2012-04-19 |
2017-11-15 |
サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. |
オリゴヌクレオチド送達のための、新規なジエステルおよびトリエステルベースの低分子量、生分解性カチオン性脂質
|
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
|
EP2859102A4
(de)
|
2012-06-08 |
2016-05-11 |
Shire Human Genetic Therapies |
Nukleaseresistente polynukleotide und verwendungen davon
|
|
EP2858679B2
(de)
|
2012-06-08 |
2024-06-05 |
Translate Bio, Inc. |
Pulmonale verabreichung von mrns an nicht pulmonale zielzellen
|
|
AU2013274235B2
(en)
|
2012-06-15 |
2018-01-18 |
Samir N. Khleif |
Cationic lipid vaccine compositions and methods of use
|
|
JP6108197B2
(ja)
*
|
2012-07-02 |
2017-04-05 |
日油株式会社 |
三級アミノ基含有脂質の製造方法
|
|
WO2014047533A1
(en)
|
2012-09-21 |
2014-03-27 |
Frank Bedu-Addo |
Improved vaccine compositions and methods of use
|
|
RS63237B1
(sr)
|
2012-11-26 |
2022-06-30 |
Modernatx Inc |
Terminalno modifikovana rnk
|
|
ES2657608T3
(es)
|
2012-12-05 |
2018-03-06 |
Alnylam Pharmaceuticals, Inc. |
Composiciones de arni de pcsk9 y métodos de uso de las mismas
|
|
WO2014093622A2
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
ES2689523T3
(es)
|
2013-03-14 |
2018-11-14 |
Translate Bio, Inc. |
Composiciones a base de ARNM del gen CFTR y métodos y usos relacionados
|
|
US9957499B2
(en)
|
2013-03-14 |
2018-05-01 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
|
CN105209490A
(zh)
|
2013-03-14 |
2015-12-30 |
夏尔人类遗传性治疗公司 |
用于递送mrna编码的抗体的方法和组合物
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
SMT201800264T1
(it)
|
2013-03-15 |
2018-07-17 |
Translate Bio Inc |
Potenziamento sinergico del rilascio di acidi nucleici attraverso formulazioni miscelate
|
|
JP6605446B2
(ja)
|
2013-03-15 |
2019-11-13 |
ザ ユニバーシティ オブ ブリティッシュ コロンビア |
形質移入用の脂質ナノ粒子および関連方法
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
KR102109188B1
(ko)
|
2013-04-01 |
2020-05-11 |
삼성전자주식회사 |
양이온성 지질을 포함하는 온도민감성 리포좀 및 그의 용도
|
|
KR20160019553A
(ko)
|
2013-06-17 |
2016-02-19 |
더 브로드 인스티튜트, 인코퍼레이티드 |
유사분열 후 세포의 질병 및 장애를 표적화하고 모델링하기 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
|
|
RU2716420C2
(ru)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
|
|
WO2014204729A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
|
CN105555757A
(zh)
*
|
2013-07-23 |
2016-05-04 |
普洛体维生物治疗公司 |
用于递送信使rna的组合物和方法
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
JP2016538829A
(ja)
|
2013-10-03 |
2016-12-15 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
低密度リポタンパク質受容体をコードするポリヌクレオチド
|
|
EA201690590A1
(ru)
|
2013-10-22 |
2016-12-30 |
Шир Хьюман Дженетик Терапис, Инк. |
ТЕРАПИЯ НЕДОСТАТОЧНОСТИ АРГИНИНОСУКЦИНАТ-СИНТЕТАЗЫ С ПОМОЩЬЮ мРНК
|
|
CN105658242A
(zh)
|
2013-10-22 |
2016-06-08 |
夏尔人类遗传性治疗公司 |
用于苯丙酮尿症的mrna疗法
|
|
EP3060257B1
(de)
|
2013-10-22 |
2021-02-24 |
Translate Bio, Inc. |
Lipidzusammensetzungen zur verabreichung von mrna
|
|
US20150110857A1
(en)
|
2013-10-22 |
2015-04-23 |
Shire Human Genetic Therapies, Inc. |
Cns delivery of mrna and uses thereof
|
|
EP3470089A1
(de)
|
2013-12-12 |
2019-04-17 |
The Broad Institute Inc. |
Freisetzung, verwendung und therapeutische anwendungen der crispr-cas-systeme und zusammensetzungen für störungen und erkrankungen mittels partikelfreisetzungskomponenten
|
|
CA2932436A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute, Inc. |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
|
EP3080271B1
(de)
|
2013-12-12 |
2020-02-12 |
The Broad Institute, Inc. |
Systeme, verfahren und zusammensetzungen zur sequenzmanipulation mit optimierten funktionellen crispr-cas-systemen
|
|
CA2932478A1
(en)
|
2013-12-12 |
2015-06-18 |
Massachusetts Institute Of Technology |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
|
|
WO2015089473A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
WO2015089465A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
|
|
US10821175B2
(en)
|
2014-02-25 |
2020-11-03 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
|
LT4023249T
(lt)
|
2014-04-23 |
2025-01-10 |
Modernatx, Inc. |
Nuleorūgšties vakcinos
|
|
CN110511927A
(zh)
|
2014-04-25 |
2019-11-29 |
川斯勒佰尔公司 |
信使rna的纯化方法
|
|
MA48050A
(fr)
|
2014-05-30 |
2020-02-12 |
Translate Bio Inc |
Lipides biodégradables pour l'administration d'acides nucléiques
|
|
WO2015192020A1
(en)
|
2014-06-13 |
2015-12-17 |
Children's Medical Center Corporation |
Products and methods to isolate mitochondria
|
|
EA033966B1
(ru)
|
2014-06-24 |
2019-12-13 |
Транслейт Био, Инк. |
Стереохимически обогащенные композиции для доставки нуклеиновых кислот
|
|
HUE060907T2
(hu)
|
2014-06-25 |
2023-04-28 |
Acuitas Therapeutics Inc |
Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
|
|
WO2016004318A1
(en)
|
2014-07-02 |
2016-01-07 |
Shire Human Genetic Therapies, Inc. |
Encapsulation of messenger rna
|
|
EP3686279B1
(de)
|
2014-08-17 |
2023-01-04 |
The Broad Institute, Inc. |
Genombearbeitung mit cas9-nickasen
|
|
EP3184506B1
(de)
*
|
2014-08-18 |
2019-07-24 |
NOF Corporation |
Kationisches lipid zur nukleinsäurefreisetzung
|
|
LT3185957T
(lt)
|
2014-08-29 |
2022-09-26 |
Alnylam Pharmaceuticals, Inc. |
Patisiranas, skirtas naudoti transtiretino amiloidozei gydyti
|
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
CN107208095B
(zh)
|
2014-10-02 |
2021-11-16 |
阿布特斯生物制药公司 |
用于使乙型肝炎病毒基因表达沉默的组合物和方法
|
|
JP6767976B2
(ja)
|
2014-12-05 |
2020-10-14 |
トランスレイト バイオ, インコーポレイテッド |
関節疾患の治療のためのメッセンジャーrna治療法
|
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
|
WO2016094872A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
|
EP3230451B1
(de)
|
2014-12-12 |
2021-04-07 |
The Broad Institute, Inc. |
Geschützte guide-rnas (pgrnas)
|
|
WO2016100974A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute Inc. |
Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
EP3702456A1
(de)
|
2014-12-24 |
2020-09-02 |
The Broad Institute, Inc. |
Crispr mit destabilisierungsdomänen oder mit destabilisierungsdomänenassoziierung
|
|
CA2975371C
(en)
|
2015-01-30 |
2024-02-13 |
Nof Corporation |
Cationic lipid for nucleic acid delivery
|
|
EP3256487A4
(de)
|
2015-02-09 |
2018-07-18 |
Duke University |
Zusammensetzungen und verfahren zur epigenombearbeitung
|
|
CA2979695C
(en)
|
2015-03-19 |
2025-02-06 |
Translate Bio, Inc. |
RNA THERAPY FOR POMPE DISEASE
|
|
CA2980721C
(en)
*
|
2015-03-24 |
2023-10-24 |
Kyowa Hakko Kirin Co., Ltd. |
Nucleic acid-containing lipid nanoparticles
|
|
US10780054B2
(en)
|
2015-04-17 |
2020-09-22 |
Curevac Real Estate Gmbh |
Lyophilization of RNA
|
|
US10729654B2
(en)
|
2015-05-20 |
2020-08-04 |
Curevac Ag |
Dry powder composition comprising long-chain RNA
|
|
US10517827B2
(en)
|
2015-05-20 |
2019-12-31 |
Curevac Ag |
Dry powder composition comprising long-chain RNA
|
|
WO2016197132A1
(en)
|
2015-06-04 |
2016-12-08 |
Protiva Biotherapeutics Inc. |
Treating hepatitis b virus infection using crispr
|
|
WO2016205745A2
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Cell sorting
|
|
EP3430134B1
(de)
|
2015-06-18 |
2022-09-21 |
The Broad Institute, Inc. |
Neue crispr enzyme und systeme
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
CA3012607A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Crispr enzymes and systems
|
|
CA2989830A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute, Inc. |
Crispr enzyme mutations reducing off-target effects
|
|
ES2984981T3
(es)
|
2015-06-29 |
2024-10-31 |
Acuitas Therapeutics Inc |
Lípidos y formulaciones de nanopartículas lipídicas para el suministro de ácidos nucleicos
|
|
WO2017019891A2
(en)
|
2015-07-29 |
2017-02-02 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing hepatitis b virus gene expression
|
|
KR20240074895A
(ko)
|
2015-07-31 |
2024-05-28 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) iRNA 조성물 및 TTR-관련 질병을 치료하거나, 예방하기 위한 그의 사용 방법
|
|
US9856481B2
(en)
|
2015-08-13 |
2018-01-02 |
Ann & Robert H. Lurie Children's Hospital |
MicroRNA treatment of fibrosis
|
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
WO2017031370A1
(en)
|
2015-08-18 |
2017-02-23 |
The Broad Institute, Inc. |
Methods and compositions for altering function and structure of chromatin loops and/or domains
|
|
MX2018002090A
(es)
|
2015-08-24 |
2018-09-12 |
Halo Bio Rnai Therapeutics Inc |
Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos.
|
|
ES2910425T3
(es)
|
2015-09-17 |
2022-05-12 |
Modernatx Inc |
Compuestos y composiciones para la administración intracelular de agentes terapéuticos
|
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
EP4089175A1
(de)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
|
|
AU2016338559B2
(en)
|
2015-10-14 |
2022-11-24 |
Translate Bio, Inc. |
Modification of RNA-related enzymes for enhanced production
|
|
WO2017070605A1
(en)
|
2015-10-22 |
2017-04-27 |
The Broad Institute Inc. |
Type vi-b crispr enzymes and systems
|
|
US11492670B2
(en)
|
2015-10-27 |
2022-11-08 |
The Broad Institute Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
SI3368507T1
(sl)
|
2015-10-28 |
2023-04-28 |
Acuitas Therapeutics Inc. |
Novi lipidi in formulacije lipidnih nanodelcev za dostavo nukleinskih kislin
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
US11612652B2
(en)
|
2015-11-13 |
2023-03-28 |
Pds Biotechnology Corporation |
Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
|
|
CN108779466B
(zh)
|
2015-11-30 |
2024-03-29 |
杜克大学 |
用于通过基因编辑修正人肌营养不良蛋白基因的治疗靶标和使用方法
|
|
EP3397260B1
(de)
|
2015-11-30 |
2025-10-15 |
Sana Biotechnology, Inc. |
Sub-mitochondrielle partikel zur verwendung bei der behandlung metabolischer erkrankungen
|
|
WO2017099823A1
(en)
|
2015-12-10 |
2017-06-15 |
Modernatx, Inc. |
Compositions and methods for delivery of therapeutic agents
|
|
US12110490B2
(en)
|
2015-12-18 |
2024-10-08 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
|
DK3394030T3
(da)
|
2015-12-22 |
2022-03-28 |
Modernatx Inc |
Forbindelser og sammensætninger til intracellulær afgivelse af midler
|
|
WO2017124037A1
(en)
|
2016-01-15 |
2017-07-20 |
The Children's Medical Center Corporation |
Therapeutic use of mitochondria and combined mitochondrial agents
|
|
KR102369898B1
(ko)
|
2016-04-08 |
2022-03-03 |
트랜슬레이트 바이오 인코포레이티드 |
다량체 코딩 핵산 및 그 용도
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
EP3445853A1
(de)
|
2016-04-19 |
2019-02-27 |
The Broad Institute, Inc. |
Cpf1-komplexe mit reduzierter indelaktivität
|
|
US12410416B2
(en)
|
2016-04-19 |
2025-09-09 |
The Broad Institute, Inc. |
CRISPR enzymes and systems with modified pam specificity
|
|
US20200263190A1
(en)
|
2016-04-19 |
2020-08-20 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
US12076397B2
(en)
*
|
2016-05-10 |
2024-09-03 |
The Regents Of The University Of Michigan |
Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
|
|
AU2017268394A1
(en)
|
2016-05-18 |
2019-01-03 |
Modernatx, Inc. |
Polynucleotides encoding relaxin
|
|
EP3842530A1
(de)
|
2016-06-13 |
2021-06-30 |
Translate Bio, Inc. |
Messenger-rna-therapie zur behandlung von ornithintranscarbamylasemangel
|
|
BR112018076190A2
(pt)
|
2016-06-17 |
2019-06-18 |
Massachusetts Inst Technology |
ortólogos e sistemas crispr tipo vi
|
|
US20210222164A1
(en)
|
2016-06-29 |
2021-07-22 |
The Broad Institute, Inc. |
Crispr-cas systems having destabilization domain
|
|
US10927383B2
(en)
|
2016-06-30 |
2021-02-23 |
Ethris Gmbh |
Cas9 mRNAs
|
|
AU2017286980B2
(en)
|
2016-06-30 |
2023-10-26 |
Arbutus Biopharma Corporation |
Compositions and methods for delivering messenger RNA
|
|
WO2018017754A1
(en)
|
2016-07-19 |
2018-01-25 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
EP3500671B1
(de)
|
2016-08-17 |
2024-07-10 |
The Broad Institute, Inc. |
Verfahren zur selektion von zielsequenzen zur entwicklung von guide rna
|
|
EP3500670B1
(de)
|
2016-08-17 |
2024-07-10 |
The Broad Institute, Inc. |
Verfahren um zielsequenzen für guide rna von crispr systemen auszuwählen
|
|
MA45999A
(fr)
|
2016-08-22 |
2019-06-26 |
Arbutus Biopharma Corp |
Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
US12499971B2
(en)
|
2016-09-28 |
2025-12-16 |
The Broad Institute, Inc. |
Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
|
|
US12447213B2
(en)
|
2016-10-07 |
2025-10-21 |
The Broad Institute, Inc. |
Modulation of novel immune checkpoint targets
|
|
CA3041307A1
(en)
|
2016-10-21 |
2018-04-26 |
Giuseppe Ciaramella |
Human cytomegalovirus vaccine
|
|
EP3532103B1
(de)
|
2016-10-26 |
2025-12-03 |
Acuitas Therapeutics, Inc. |
Lipidnanopartikelformulierung
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US11459568B2
(en)
|
2016-10-31 |
2022-10-04 |
University Of Massachusetts |
Targeting microRNA-101-3p in cancer therapy
|
|
WO2018089540A1
(en)
|
2016-11-08 |
2018-05-17 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
EA201991747A1
(ru)
|
2017-02-27 |
2020-06-04 |
Транслейт Био, Инк. |
НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
|
|
US11203569B2
(en)
|
2017-03-15 |
2021-12-21 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
US11464848B2
(en)
|
2017-03-15 |
2022-10-11 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
EP3609534A4
(de)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
Influenza-virus-impfstoff mit breitem spektrum
|
|
ES3020935T3
(en)
|
2017-03-15 |
2025-05-23 |
Modernatx Inc |
Lipid nanoparticle formulation
|
|
LT3596041T
(lt)
|
2017-03-15 |
2023-01-25 |
Modernatx, Inc. |
Terapinių medžiagų, skirtų intraląsteliniam tiekimui, junginys ir sudėtys
|
|
EP3596207B1
(de)
|
2017-03-15 |
2023-12-20 |
The Broad Institute, Inc. |
Neuartige cas13b-orthologe-crispr-enzyme und systeme
|
|
WO2019012336A2
(en)
|
2017-03-17 |
2019-01-17 |
Newcastle University |
ADENO-ASSOCIATED VIRAL VECTOR DELIVERY OF A MICRO-DYSTROPHIN FRAGMENT FOR TREATING MUSCLE DYSTROPHY
|
|
US11433026B2
(en)
*
|
2017-03-31 |
2022-09-06 |
University Of Rhode Island Board Of Trustees |
Nanoparticle-induced fusogenicity between liposome and endosome membranes for targeted delivery through endosomal escape
|
|
MA48047A
(fr)
|
2017-04-05 |
2020-02-12 |
Modernatx Inc |
Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
|
|
EP3610009A1
(de)
|
2017-04-12 |
2020-02-19 |
The Broad Institute, Inc. |
Neuartige typ-vi-crispr-orthologe und systeme
|
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
US12350368B2
(en)
|
2017-04-14 |
2025-07-08 |
The Broad Institute, Inc. |
Delivery of large payloads
|
|
CA3061612A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
WO2018204777A2
(en)
|
2017-05-05 |
2018-11-08 |
The Broad Institute, Inc. |
Methods for identification and modification of lncrna associated with target genotypes and phenotypes
|
|
MX2019013312A
(es)
|
2017-05-08 |
2020-08-17 |
Flagship Pioneering Innovations V Inc |
Composiciones para facilitar la fusion de membranas y usos de estas.
|
|
EP3624824B1
(de)
|
2017-05-16 |
2024-07-10 |
Translate Bio, Inc. |
Codonoptimierter mrna, die cftr codiert, zur verwendung in der behandlung von zystischer fibrose
|
|
US12297436B2
(en)
|
2017-05-18 |
2025-05-13 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
KR20200038236A
(ko)
|
2017-06-13 |
2020-04-10 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
큐론을 포함하는 조성물 및 그의 용도
|
|
US12077501B2
(en)
|
2017-06-14 |
2024-09-03 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
EP3638215A4
(de)
|
2017-06-15 |
2021-03-24 |
Modernatx, Inc. |
Rna-formulierungen
|
|
US20210228738A1
(en)
|
2017-07-17 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
|
|
WO2019036008A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
JP7461872B2
(ja)
|
2017-08-17 |
2024-04-04 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
MX2020002348A
(es)
|
2017-08-31 |
2020-10-08 |
Modernatx Inc |
Métodos de elaboración de nanopartículas lipídicas.
|
|
WO2019045897A1
(en)
|
2017-08-31 |
2019-03-07 |
Life Technologies Corporation |
CATIONIC LIPIDIC COMPOSITIONS FOR TISSUE-SPECIFIC ADMINISTRATION
|
|
KR20200089656A
(ko)
|
2017-09-19 |
2020-07-27 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
|
|
WO2019060746A1
(en)
|
2017-09-21 |
2019-03-28 |
The Broad Institute, Inc. |
SYSTEMS, METHODS, AND COMPOSITIONS FOR THE TARGETED EDITING OF NUCLEIC ACIDS
|
|
WO2019071054A1
(en)
|
2017-10-04 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF BUCKLES AND / OR CHROMATIN DOMAINS
|
|
WO2019135816A2
(en)
|
2017-10-23 |
2019-07-11 |
The Broad Institute, Inc. |
Novel nucleic acid modifiers
|
|
US11547614B2
(en)
|
2017-10-31 |
2023-01-10 |
The Broad Institute, Inc. |
Methods and compositions for studying cell evolution
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
EP3710039A4
(de)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
Verfahren und zusammensetzungen zur behandlung von krebs durch targeting des clec2d-klrb1-wegs
|
|
TW201936201A
(zh)
|
2017-12-14 |
2019-09-16 |
美商堅固生物科技公司 |
基因之非病毒生產及遞送
|
|
WO2019126593A1
(en)
|
2017-12-20 |
2019-06-27 |
Translate Bio, Inc. |
Improved composition and methods for treatment of ornithine transcarbamylase deficiency
|
|
US20230193242A1
(en)
|
2017-12-22 |
2023-06-22 |
The Broad Institute, Inc. |
Cas12b systems, methods, and compositions for targeted dna base editing
|
|
WO2019131829A1
(ja)
|
2017-12-28 |
2019-07-04 |
国立大学法人京都大学 |
標的遺伝子改変用組成物
|
|
EP3733641B1
(de)
|
2017-12-28 |
2024-04-10 |
Takeda Pharmaceutical Company Limited |
Kationische lipide
|
|
EP3740580A4
(de)
|
2018-01-19 |
2021-10-20 |
Duke University |
Genom-engineering mit crispr-cas-systemen bei eukaryonten
|
|
MA54676A
(fr)
|
2018-01-29 |
2021-11-17 |
Modernatx Inc |
Vaccins à base d'arn contre le vrs
|
|
CA3094057C
(en)
|
2018-03-27 |
2025-04-08 |
Nof Corporation |
CATIONIC LIPID WITH IMPROVED INTRACELLULAR DYNAMICS
|
|
FI3807413T3
(fi)
|
2018-06-18 |
2025-08-13 |
Res Inst Nationwide Childrens Hospital |
Lihasspesifisen mikrodystrofiinin annostelu adeno-assosioituneella virusvektorilla lihasdystrofian hoitamiseksi
|
|
US10736847B2
(en)
|
2018-07-03 |
2020-08-11 |
Becton, Dickinson And Company |
Inverting device for liposome preparation by centrifugation
|
|
WO2020033601A1
(en)
|
2018-08-07 |
2020-02-13 |
The Broad Institute, Inc. |
Novel cas12b enzymes and systems
|
|
JP2021534101A
(ja)
|
2018-08-09 |
2021-12-09 |
ヴェルソー セラピューティクス, インコーポレイテッド |
Ccr2及びcsf1rを標的とするためのオリゴヌクレオチド組成物ならびにその使用
|
|
WO2020041380A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
|
EP3841208A1
(de)
|
2018-08-24 |
2021-06-30 |
Translate Bio, Inc. |
Verfahren zur reinigung von messenger-rna
|
|
EP3853202A1
(de)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Verbindungen und zusammensetzungen zur intrazellulären verabreichung von therapeutischen wirkstoffen
|
|
CN112996854B
(zh)
|
2018-09-19 |
2024-08-30 |
摩登纳特斯有限公司 |
高纯度peg脂质和其用途
|
|
MA53650A
(fr)
|
2018-09-19 |
2021-07-28 |
Modernatx Inc |
Lipides peg et leurs utilisations
|
|
EP3852728B1
(de)
|
2018-09-20 |
2024-09-18 |
ModernaTX, Inc. |
Herstellung von lipidnanopartikeln und verfahren zu deren verabreichung
|
|
CA3113449A1
(en)
|
2018-09-21 |
2020-03-26 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
KR20210092717A
(ko)
*
|
2018-10-01 |
2021-07-26 |
요하네스 구텐베르크-유니버시타트 마인츠 |
폴리사르코신을 포함하는 rna 입자
|
|
EA202190688A1
(ru)
|
2018-10-09 |
2021-06-07 |
Дзе Юниверсити Оф Бритиш Коламбиа |
Композиции и системы, содержащие трансфекционно-компетентные везикулы, не содержащие органических растворителей и детергентов, и связанные с ними способы
|
|
AU2019384557B2
(en)
|
2018-11-21 |
2025-07-17 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
|
|
US11166996B2
(en)
|
2018-12-12 |
2021-11-09 |
Flagship Pioneering Innovations V, Inc. |
Anellovirus compositions and methods of use
|
|
FI3908568T3
(fi)
|
2019-01-11 |
2024-09-13 |
Acuitas Therapeutics Inc |
Lipidit aktiivisten aineiden lipidinanohiukkastoimitusta varten
|
|
WO2020190750A1
(en)
|
2019-03-15 |
2020-09-24 |
Modernatx, Inc. |
Hiv rna vaccines
|
|
WO2020191102A1
(en)
|
2019-03-18 |
2020-09-24 |
The Broad Institute, Inc. |
Type vii crispr proteins and systems
|
|
US20220204994A1
(en)
|
2019-04-05 |
2022-06-30 |
Precision Biosciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
|
US20220220469A1
(en)
|
2019-05-20 |
2022-07-14 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
|
WO2020247882A1
(en)
|
2019-06-07 |
2020-12-10 |
Scribe Therapeutics Inc. |
Engineered casx systems
|
|
JP7753190B2
(ja)
|
2019-08-14 |
2025-10-14 |
アクイタス セラピューティクス インコーポレイテッド |
核酸の送達のための改善された脂質ナノ粒子
|
|
BR112022004759A2
(pt)
|
2019-09-19 |
2022-06-21 |
Modernatx Inc |
Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos
|
|
IL296133A
(en)
|
2020-03-04 |
2022-11-01 |
Verve Therapeutics Inc |
Preparations and methods for administering targeted RNA
|
|
US20230150926A1
(en)
|
2020-03-17 |
2023-05-18 |
Genevant Sciences Gmbh |
Cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
|
|
WO2021195218A1
(en)
|
2020-03-24 |
2021-09-30 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
|
AU2021244555A1
(en)
|
2020-03-24 |
2022-11-24 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
|
CA3174588A1
(en)
|
2020-03-30 |
2021-10-07 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
IL299094A
(en)
|
2020-06-15 |
2023-02-01 |
Res Inst Nationwide Childrens Hospital |
Administration of an adeno-associated virus vector for muscular dystrophies
|
|
WO2025056938A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
IL299787A
(en)
|
2020-07-16 |
2023-03-01 |
Acuitas Therapeutics Inc |
Cationic lipids for use in lipid nanoparticles
|
|
AU2021314809A1
(en)
|
2020-07-27 |
2023-02-23 |
Anjarium Biosciences Ag |
Compositions of DNA molecules, methods of making therefor, and methods of use thereof
|
|
KR20230167008A
(ko)
*
|
2020-08-06 |
2023-12-07 |
모더나티엑스, 인크. |
지질 나노입자의 제조 방법
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
US20230365995A1
(en)
|
2020-10-07 |
2023-11-16 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
|
WO2022081752A1
(en)
|
2020-10-14 |
2022-04-21 |
George Mason Research Foundation, Inc. |
Methods of lipid nanoparticle manufacture and compostions derived therefrom
|
|
TW202233232A
(zh)
|
2020-11-06 |
2022-09-01 |
法商賽諾菲公司 |
遞送mRNA疫苗的脂質奈米顆粒
|
|
KR20230124927A
(ko)
|
2020-11-25 |
2023-08-28 |
아카제라 메디신즈, 인크. |
핵산 전달을 위한 지질 나노입자, 및 관련 사용 방법
|
|
JP2023552374A
(ja)
|
2020-12-03 |
2023-12-15 |
スクライブ・セラピューティクス・インコーポレイテッド |
操作されたクラス2 v型crisprシステム
|
|
EP4617367A3
(de)
|
2020-12-18 |
2025-12-10 |
Genevant Sciences Gmbh |
Peg-lipide und lipidnanopartikel
|
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
EP4319803B1
(de)
|
2021-04-08 |
2025-11-26 |
Vaxthera SAS |
Mosaikproteinhaltige coronavirus-impstoff
|
|
CA3214538A1
(en)
|
2021-04-20 |
2022-10-27 |
Joel DE BEER |
Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
|
|
US20240226324A1
(en)
|
2021-04-27 |
2024-07-11 |
Generation Bio Co. |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
|
EP4329884A1
(de)
|
2021-04-27 |
2024-03-06 |
Generation Bio Co. |
Nichtvirale dna-vektoren zur expression von anti-coronavirus-antikörpern und verwendungen davon
|
|
KR20240018446A
(ko)
|
2021-06-08 |
2024-02-13 |
씨4 테라퓨틱스, 인코포레이티드 |
돌연변이 braf의 분해를 위한 요법
|
|
WO2022260480A1
(ko)
|
2021-06-11 |
2022-12-15 |
주식회사 나이벡 |
타겟 세포 내로 올리고뉴클레오티드를 전달하기 위한 펩타이드-지질의 결합체를 포함하는 나노입자 및 이를 포함하는 약학적 조성물
|
|
EP4352215A1
(de)
|
2021-06-11 |
2024-04-17 |
LifeEDIT Therapeutics, Inc. |
Rna-polymerase-iii-promotoren und verfahren zur verwendung
|
|
AU2022301302A1
(en)
|
2021-07-01 |
2024-01-25 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
|
US20230044997A1
(en)
|
2021-07-15 |
2023-02-09 |
Turn Biotechnologies, Inc. |
Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment
|
|
WO2023288288A1
(en)
|
2021-07-15 |
2023-01-19 |
Turn Biotechnologies, Inc. |
Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use
|
|
WO2023288285A1
(en)
|
2021-07-15 |
2023-01-19 |
Turn Biotechnologies, Inc. |
Polycistronic expression vectors
|
|
WO2023010135A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
EP4377459A2
(de)
|
2021-07-30 |
2024-06-05 |
Tune Therapeutics, Inc. |
Zusammensetzungen und verfahren zur modulation der expression von frataxin (fxn)
|
|
EP4381067A1
(de)
|
2021-08-03 |
2024-06-12 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
JP2024534697A
(ja)
|
2021-09-14 |
2024-09-20 |
レナゲード セラピューティクス マネージメント インコーポレイテッド |
非環状脂質及びその使用方法
|
|
JP2024533865A
(ja)
|
2021-09-14 |
2024-09-12 |
レナゲード セラピューティクス マネージメント インコーポレイテッド |
環状脂質及びその使用方法
|
|
JP2024539512A
(ja)
|
2021-10-22 |
2024-10-28 |
セイル バイオメディシンズ インコーポレイテッド |
Mrnaワクチン組成物
|
|
EP4426832A1
(de)
|
2021-11-03 |
2024-09-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Genaue genomeditierung mit retrons
|
|
CA3236235A1
(en)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
|
CA3238292A1
(en)
|
2021-11-16 |
2023-05-25 |
Alessandra Bartolozzi |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
MX2024006134A
(es)
|
2021-11-22 |
2024-07-29 |
Sail Biomedicines Inc |
Lipidos ionizables novedosos y nanoparticulas de lipido y metodos para usar los mismos.
|
|
US20250002941A1
(en)
|
2021-11-23 |
2025-01-02 |
Sail Biomedicines, Inc. |
A bacteria-derived lipid composition and use thereof
|
|
US12129223B2
(en)
|
2021-12-16 |
2024-10-29 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
JP2025500373A
(ja)
|
2021-12-20 |
2025-01-09 |
セイル バイオメディシンズ インコーポレイテッド |
Mrna治療用組成物
|
|
EP4452928A1
(de)
|
2021-12-23 |
2024-10-30 |
Renagade Therapeutics Management Inc. |
Eingeschränkte lipide und verfahren zur verwendung davon
|
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
JP2025504404A
(ja)
|
2022-01-14 |
2025-02-12 |
アンジャリウム バイオサイエンシズ エージー |
Viii因子をコードするdna分子の組成物、それを作製する方法、及びその使用方法
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
IL314324A
(en)
|
2022-01-27 |
2024-09-01 |
BioNTech SE |
Pharmaceutical preparations for administration of herpes simplex virus antigens and related methods
|
|
ES3017428T3
(en)
|
2022-01-31 |
2025-05-12 |
Genevant Sciences Gmbh |
Ionizable cationic lipids for lipid nanoparticles
|
|
US20250144235A1
(en)
|
2022-02-02 |
2025-05-08 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
CA3245737A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
PRIME-BOOST HETEROLOGICAL VACCINE COMPOSITIONS AND METHODS OF USE
|
|
CN119072464A
(zh)
|
2022-03-25 |
2024-12-03 |
赛欧生物医药股份有限公司 |
新型可电离脂质和脂质纳米颗粒以及其使用方法
|
|
WO2023196818A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
|
AU2023251104A1
(en)
|
2022-04-07 |
2024-10-17 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
|
CA3249579A1
(en)
|
2022-05-05 |
2023-11-09 |
Stichting Genetische Hartspierziekte Pln |
RNA INTERFERENCE THERAPY FOR CARDIOMYOPATHY PLN-R14DEL
|
|
CN119604610A
(zh)
|
2022-05-09 |
2025-03-11 |
瑞泽恩制药公司 |
用于体内抗体产生的载体和方法
|
|
AU2023268051A1
(en)
|
2022-05-13 |
2025-01-02 |
BioNTech SE |
Rna compositions targeting hiv
|
|
US12064479B2
(en)
|
2022-05-25 |
2024-08-20 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
|
CA3253434A1
(en)
|
2022-05-25 |
2023-11-30 |
BioNTech SE |
RNA COMPOSITIONS FOR THE ADMINISTRATION OF MONKEY POULTRY ANTIGENS AND ASSOCIATED METHODS
|
|
EP4534108A1
(de)
|
2022-05-30 |
2025-04-09 |
Kyushu University, National University Corporation |
Zusammensetzung mit anionischem langkettigem lipid zur abschwächung der hautbarrierefunktion und dispersion mit komplex mit kationischem langkettigem lipid
|
|
WO2023232747A1
(en)
|
2022-05-30 |
2023-12-07 |
BioNTech SE |
Complexes for delivery of nucleic acids
|
|
TW202411426A
(zh)
|
2022-06-02 |
2024-03-16 |
美商斯奎柏治療公司 |
經工程化的2類v型crispr系統
|
|
CA3258303A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Compositions of lipid nanoparticles and their uses
|
|
TW202413643A
(zh)
|
2022-06-07 |
2024-04-01 |
美商斯奎柏治療公司 |
用於靶向pcsk9的組合物及方法
|
|
JP2025524360A
(ja)
|
2022-06-07 |
2025-07-30 |
スクライブ・セラピューティクス・インコーポレイテッド |
Pcsk9の標的化のための組成物及び方法
|
|
AU2023289696A1
(en)
|
2022-06-24 |
2025-01-16 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
|
AU2023299307A1
(en)
|
2022-06-30 |
2025-01-09 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
|
CA3261203A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS OF ADMINISTRATION MEDIATED BY THE TRANSFERRIN RECEPTOR (TFR) TO THE BRAIN AND MUSCLE
|
|
AU2023323547A1
(en)
|
2022-08-12 |
2025-03-20 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
IL318767A
(en)
|
2022-08-19 |
2025-04-01 |
Tune Therapeutics Inc |
Compounds, systems and methods for regulating hepatitis B virus through targeted gene repression
|
|
CA3265596A1
(en)
|
2022-08-31 |
2024-03-07 |
Sail Biomedicines, Inc. |
NEW IONIZABLE LIPIDS AND LIPID NANOPARTICLES, AS WELL AS ASSOCIATED METHODS OF USE
|
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
|
IL319414A
(en)
|
2022-09-23 |
2025-05-01 |
BioNTech SE |
Compositions for delivering antigens at the liver level and related methods
|
|
CN120152736A
(zh)
|
2022-09-23 |
2025-06-13 |
生物技术欧洲股份公司 |
用于递送疟原虫csp抗原的组合物及相关方法
|
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
JP2025534447A
(ja)
|
2022-10-06 |
2025-10-15 |
バイオエヌテック エスエー |
クローディン18.2を標的とするrna組成物
|
|
WO2024098002A1
(en)
|
2022-11-04 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
|
JP2025537178A
(ja)
|
2022-11-08 |
2025-11-14 |
オーナ セラピューティクス, インコーポレイテッド |
環状rna組成物
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024102434A1
(en)
|
2022-11-10 |
2024-05-16 |
Senda Biosciences, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
|
JP2025538220A
(ja)
|
2022-11-14 |
2025-11-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
アストロサイトへの線維芽細胞増殖因子受容体3媒介送達のための組成物および方法
|
|
CN120615013A
(zh)
|
2022-12-01 |
2025-09-09 |
世代生物公司 |
用于细胞靶向的隐形脂质纳米颗粒组合物
|
|
AU2023406303A1
(en)
|
2022-12-01 |
2025-05-29 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses
|
|
AU2023406321A1
(en)
|
2022-12-01 |
2025-05-29 |
Generation Bio Co. |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
WO2024119103A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
EP4631527A1
(de)
|
2022-12-09 |
2025-10-15 |
Seoul National University R&DB Foundation |
Nanopartikel mit peptidbasiertem konjugat zur abgabe von mrna in eine b-zelle und t-zelle und verwendungen davon
|
|
EP4631528A1
(de)
|
2022-12-09 |
2025-10-15 |
Nibec Co., Ltd. |
Nanopartikel mit peptidbasiertem konjugat zur abgabe eines oligonukleotids in eine zielzelle und pharmazeutische zusammensetzung damit
|
|
EP4637717A1
(de)
*
|
2022-12-23 |
2025-10-29 |
Pfizer Inc. |
Lipidpartikelzusammensetzungen und verfahren zur verwendung davon
|
|
CN121127490A
(zh)
|
2022-12-28 |
2025-12-12 |
生物技术欧洲股份公司 |
靶向hiv的rna组合物
|
|
KR20250153793A
(ko)
|
2023-01-27 |
2025-10-27 |
세일 바이오메디슨스, 인크. |
변형된 지질 조성물 및 이의 용도
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
WO2024206555A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
|
TW202444914A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
抑制子融合蛋白系統
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
TW202444921A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
用於靶向lpa之組合物及方法
|
|
WO2024220625A1
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
|
|
WO2024220653A1
(en)
|
2023-04-19 |
2024-10-24 |
Gradalis, Inc. |
Compositions and methods for modulating sialic acid production and treating hereditary inclusion body myopathy (hibm)
|
|
WO2024220752A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Rna therapeutic compositions
|
|
WO2024220712A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Vaccine compositions
|
|
CN121038807A
(zh)
|
2023-05-03 |
2025-11-28 |
生物技术欧洲股份公司 |
优化的csp变体及相关方法
|
|
AU2024266138A1
(en)
|
2023-05-03 |
2025-11-13 |
Manifold Biotechnologies, Inc. |
Methods and compositions for high-throughput protein delivery, screening, and detection
|
|
WO2024228044A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
DE102023001946A1
(de)
|
2023-05-12 |
2024-11-14 |
Friedrich-Schiller-Universität Jena, Körperschaft des öffentlichen Rechts |
Nanopartikel für den Transport von Wirkstoffen mit anionischen Gruppen, Verfahren zu deren Herstellung und deren Verwendung
|
|
US20250135006A1
(en)
|
2023-07-07 |
2025-05-01 |
Pfizer Inc. |
Amphiphilic tlr7/8 adjuvants and uses thereof
|
|
WO2025024324A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
AU2024301077A1
(en)
|
2023-07-21 |
2026-01-08 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025024337A1
(en)
|
2023-07-24 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025022367A2
(en)
|
2023-07-27 |
2025-01-30 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
WO2025029835A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating il-2 gene expression
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
WO2025026545A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thioplipids and uses thereof
|
|
WO2025027089A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thiolipids and uses thereof
|
|
WO2025030154A1
(en)
|
2023-08-03 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
|
|
WO2025027576A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025030097A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
WO2025027579A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
WO2025052278A1
(en)
|
2023-09-05 |
2025-03-13 |
Genevant Sciences Gmbh |
Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025054556A1
(en)
|
2023-09-07 |
2025-03-13 |
BioNTech SE |
Rna compositions for delivery of mpox antigens and related methods
|
|
TW202540154A
(zh)
|
2023-09-11 |
2025-10-16 |
德商拜恩技術股份公司 |
用於遞送腸促胰島素劑之rna組合物
|
|
WO2025059073A1
(en)
|
2023-09-11 |
2025-03-20 |
Tune Therapeutics, Inc. |
Epigenetic editing methods and systems for differentiating stem cells
|
|
WO2025064850A1
(en)
|
2023-09-22 |
2025-03-27 |
BioNTech SE |
Rna constructs with n-terminal degrons to enhance an immune response
|
|
WO2025072383A1
(en)
|
2023-09-25 |
2025-04-03 |
The Broad Institute, Inc. |
Viral open reading frames, uses thereof, and methods of detecting the same
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025083619A1
(en)
|
2023-10-18 |
2025-04-24 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and acive fragments and variants thereof and methods of use
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
WO2025106754A1
(en)
|
2023-11-15 |
2025-05-22 |
BioNTech SE |
Coronavirus vaccine
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
WO2025129158A1
(en)
|
2023-12-15 |
2025-06-19 |
The Broad Institute, Inc. |
Engineered arc delivery vesicles and uses thereof
|
|
WO2025134066A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
TW202525287A
(zh)
|
2023-12-21 |
2025-07-01 |
德商拜恩技術運輸科技有限責任公司 |
可離子化脂質
|
|
WO2025133105A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Compositions and methods
|
|
WO2025149492A1
(en)
|
2024-01-08 |
2025-07-17 |
BioNTech SE |
Rna encoding an immune inhibitory il-1 family member
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025166323A2
(en)
|
2024-02-02 |
2025-08-07 |
Editas Medicine, Inc. |
Crispr-related methods and compositions targeting lipoprotein (a) expression
|
|
WO2025174908A1
(en)
|
2024-02-12 |
2025-08-21 |
Life Edit Therapeutics, Inc. |
Novel rna-guided nucleases and proteins for polymerase editing
|
|
WO2025184508A1
(en)
|
2024-03-01 |
2025-09-04 |
Acuitas Therapeutics, Inc. |
Materials and methods for encapsulating therapeutics in lipid nanoparticles
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
WO2025213138A1
(en)
|
2024-04-05 |
2025-10-09 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
|
|
WO2025213131A1
(en)
|
2024-04-05 |
2025-10-09 |
BioNTech SE |
Rna compositions for delivery of orthopox antigens and related methods
|
|
WO2025240940A1
(en)
|
2024-05-17 |
2025-11-20 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of apolipoprotein c3
|
|
WO2025250808A1
(en)
|
2024-05-29 |
2025-12-04 |
The Brigham And Women’S Hospital, Inc. |
Anti-crispr delivery compositions and methods
|
|
WO2025262460A1
(en)
|
2024-06-21 |
2025-12-26 |
BioNTech SE |
Lipid compositions for nucleic acid delivery
|
|
WO2026003754A1
(en)
|
2024-06-25 |
2026-01-02 |
Life Edit Therapeutics, Inc. |
Novel reverse transcriptases and uses thereof
|
|
WO2026003582A2
(en)
|
2024-06-27 |
2026-01-02 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2026015647A1
(en)
|
2024-07-09 |
2026-01-15 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1
|
|
WO2026015882A1
(en)
|
2024-07-12 |
2026-01-15 |
BioNTech SE |
Hsv antigen fragments and related methods
|
|
WO2026018213A1
(en)
|
2024-07-18 |
2026-01-22 |
Vaxthera Sas |
A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses
|
|
WO2026020171A2
(en)
|
2024-07-19 |
2026-01-22 |
Aera Therapeutics, Inc. |
Chimeric antigen receptor constructs
|